高级搜索

LSD1调控Foxo3a对卵巢癌细胞增殖和迁移的影响

王品昊, 钱尧, 周昱霖, 魏野, 吴朝阳

王品昊, 钱尧, 周昱霖, 魏野, 吴朝阳. LSD1调控Foxo3a对卵巢癌细胞增殖和迁移的影响[J]. 肿瘤防治研究, 2018, 45(8): 545-549. DOI: 10.3971/j.issn.1000-8578.2018.17.1548
引用本文: 王品昊, 钱尧, 周昱霖, 魏野, 吴朝阳. LSD1调控Foxo3a对卵巢癌细胞增殖和迁移的影响[J]. 肿瘤防治研究, 2018, 45(8): 545-549. DOI: 10.3971/j.issn.1000-8578.2018.17.1548
WANG Pinhao, QIAN Yao, ZHOU Yulin, WEI Ye, WU Chaoyang. Effect of LSD1 on Proliferation and Metastasis of Ovarian Cancer Cells by Regulating Foxo3a[J]. Cancer Research on Prevention and Treatment, 2018, 45(8): 545-549. DOI: 10.3971/j.issn.1000-8578.2018.17.1548
Citation: WANG Pinhao, QIAN Yao, ZHOU Yulin, WEI Ye, WU Chaoyang. Effect of LSD1 on Proliferation and Metastasis of Ovarian Cancer Cells by Regulating Foxo3a[J]. Cancer Research on Prevention and Treatment, 2018, 45(8): 545-549. DOI: 10.3971/j.issn.1000-8578.2018.17.1548

LSD1调控Foxo3a对卵巢癌细胞增殖和迁移的影响

详细信息
    作者简介:

    王品昊(1991-),男,硕士在读,主要从事肿瘤分子生物学的研究

    通讯作者:

    吴朝阳,E-mail:wuchaoyang9@163.com

  • 中图分类号: R737.31

Effect of LSD1 on Proliferation and Metastasis of Ovarian Cancer Cells by Regulating Foxo3a

More Information
  • 摘要:
    目的 

    探讨赖氨酸特异性去甲基化酶1(LSD1)如何通过调控转录因子Foxo3a影响卵巢癌细胞增殖和迁移。

    方法 

    实验组A:取诱导型稳定干扰LSD1表达的人卵巢癌HO8910细胞株(HO8910-LSD1-shRNA)分为观察组和对照组,蛋白质印迹法检测LSD1和Foxo3a蛋白表达水平;实验组B:将HO8910-LSD1-shRNA细胞分为对照组、Dox组、A6730组和联合组,CCK-8检测各组细胞增殖抑制率,Transwell小室检测各组细胞迁移能力,蛋白质印迹法检测EMT相关蛋白表达。

    结果 

    在实验组A中,观察组LSD1蛋白水平随Dox浓度增加逐渐下降,而Foxo3a蛋白表达水平逐渐升高。在实验组B中,与对照组比较,Dox组、A6730组和联合组细胞增殖抑制率、细胞迁移率均显著减少(均P < 0.05);联合组较Dox组,细胞增殖抑制率、细胞迁移率均显著减少(均P < 0.05)。与对照组比较,Dox组、A6730组和联合组E-cadherin蛋白表达水平明显升高,而N-cadherin和Snail蛋白水平降低。与Dox组和A6730组比较,联合组E-cadherin表达量增加,而N-cadherin及Snail表达量减少。

    结论 

    敲低LSD1基因表达可以上调转录因子Foxo3a蛋白水平,从而抑制卵巢癌HO8910细胞增殖和转移。

     

    Abstract:
    Objective 

    To investigate the effects of lysine-specific demethylation 1 (LSD1) on the proliferation and metastasis of ovarian cancer cells by regulating Foxo3a.

    Methods 

    In test group A, the human ovarian cancer cell line HO8910 (HO8910-LSD1-shRNA) with inducible stable knockdown of LSD1 expressions were divided into the observation groups and the control group. The expression levels of LSD1 and Foxo3a proteins were detected by Western blot. Then in test group B, the HO8910-LSD1-shRNA cells were divided into Control group, Dox group, A6730 group and Dox+A6730 group. The cell proliferation inhibition rate of each group was detected by CCK-8, and the metastasis levels of each group were detected by Transwell assay. The EMT-related proteins expressions were detected by Western blot.

    Results 

    In test group A, with the increasing Dox concentration in the observation groups, the expression level of LSD1 protein was gradually decreased, while the expression level of Foxo3a protein was gradually increased. In test group B, compared with the control group, the proliferation inhibition rates, cell migration rates of Dox group, A6730 group and combination group were significantly lower (P < 0.05); cell proliferation inhibition rate and cell migration rate of the Dox+A6730 group were significantly lower than those of Dox group (both P < 0.05). Compared with the control group, the expression levels of E-cadherin protein in Dox group, A6730 group and combination group were increased significantly, while the levels of N-cadherin and Snail protein were decreased. Compared with Dox and A6730 groups, the expression of E-cadherin was increased, while the expression of N-cadherin and Snail were decreased in the combination group.

    Conclusion 

    Knocking down the expression of LSD1 gene could upregulate the transcription factor Foxo3a protein level, thereby inhibiting the proliferation metastasis of ovarian cancer HO8910 cells.

     

  • 胶质母细胞瘤(glioblastoma multiforme,GBM)为恶性程度最高的星形细胞瘤(属WHO分级的Ⅳ级)。临床上,由于该肿瘤呈浸润性快速生长,多数患者,颅内压迫症状严重,手术清除难度大。即便在手术配合放化疗治疗方案下,绝大多数GBM患者仍因肿瘤复发死亡,中位生存时间只有14~18月[1-2]。临床上,无论是原发或继发GBM患者,肿瘤的基因背景与生物学行为都具有不均一性,因此,每个患者都需进行个体化的治疗决策和预后判断。目前,应用于GBM的临床诊断技术和肿瘤监测手段仍比较单一(主要为影像学技术),存在缺陷,不利于GBM的个体化治疗决策,寻找新的更有效的检测手段迫在眉睫。

    近年来,随着生物检测技术的发展,GBM患者血液中检测到肿瘤细胞已是不争的事实[3-4],这些与GBM的复发密切相关的细胞称为循环肿瘤细胞(circulating tumor cells, CTCs),它们的检测也被誉为“循环活检”。尽管文献报道不多,CTCs的发现给GBM患者的诊治带来了新的希望,它在GBM的早期诊断、肿瘤复发风险评估和预后评估等方面具有潜在的临床应用价值,使GBM诊治的决策更加“有章可循”。本文就胶质母细胞瘤CTCs的一些研究进展综述如下。

    九十年代初,科学家们用免疫细胞化学和克隆形成实验技术检测到乳腺癌患者外周血中的肿瘤细胞后,CTCs的检测和应用逐渐受到重视[5]。迄今已有多项研究表明,GBM患者与一些肿瘤(乳腺癌、前列腺癌、结直肠癌等)患者一样,血液中可以检测到CTCs[3-4, 6-7]。但在外周血中,CTCs受血流剪应力、失巢凋亡和免疫细胞识别杀伤等因素的影响,绝大多数发生死亡[8],这给CTCs的检测带来了极大的挑战。

    有研究认为GBM患者中的CTCs来源于一群具有高度繁殖、自我更新、分化的能力的细胞群体,称为GBM肿瘤干细胞(glioblastoma stem cells, GSC)[8];GSC具有较高的成瘤潜质,且能够通过神经上皮间质转换过程(glio-mesenchymal transition, GMT)[9]逃脱原发的肿瘤组织,由微脉管入侵循环系统,最后在远处或原发部位种植,完成肿瘤的转移和复发。肿瘤患者血液中幸存的CTCs不仅具有增殖、侵袭和迁移能力,而且具有极强的环境适应能力,对于放化疗具有一定的抵抗性,表现出明显的干细胞特性[10]。这种特性可解释GBM各种治疗效果不理想、易复发、预后极差的原因。

    绝大多数GBM最终会复发。手术治疗很难做到完全清除肿瘤细胞,其目的更多是为了减轻瘤负荷、缓解症状、明确病理。GBM复发机制复杂,除了与肿瘤的分化程度、手术切除范围、放化疗敏感度等因素有关外,与进入循环的肿瘤细胞也有关,Macarthur等[6]在胶母CTCs的检测中发现,在术后化疗的GBM患者血液中,肿瘤细胞较术前明显减少,遗憾的是该研究未能对患者的预后进行统计分析。

    GBM复发的机制有多种观点,有研究认为GBM肿瘤干细胞(GSC)是GBM复发的主要原因。GSC相邻的肿瘤细胞会通过旁分泌和细胞接触等方式抑制GSC,使GSC进入休眠状态。在特定的情况下,如手术、化疗、肿瘤细胞脱落入血等因素影响,使静止的GSC与周围肿瘤细胞隔开,增殖能力将会被重新激活。这种静止又被重新激活的GSC按激活部位的不同分为两类:(1)原发灶的GSC;(2)脱落入血的GSC——CTCs。它们都可能是导致GBM复发的主要因素[11-12]

    研究报道虽然显示GBM极少发生其他器官的转移(仅0.4%的GBM患者伴有肝脏、脾脏、肾脏及皮肤的转移)[13-14],但是大多数GBM最终都会复发,其中约2/3复发区域位于原发肿瘤附近(≤2 cm),由原发灶的GSC激活所致。而远处复发(> 2 cm)约占1/6的复发性GBM,发生于对侧大脑半球、其他脑叶或幕下等[15]。一些观点认为,远处复发的GBM并非源于原发肿瘤,而是在放化疗或其他因素下诱导发生,属于新原发肿瘤。而一些研究持有不同的观点,认为GBM的复发起源于原发肿瘤,并提出远处复发的肿瘤与原发肿瘤的基因具有一定的相似性[16]。也就是说,CTCs是导致肿瘤在远处复发的原因,这也是复发肿瘤与原发肿瘤基因相似性的原因,放化疗则可能诱导了CTCs的发生。

    目前,CellSearch系统是美国食品药品监督管理局唯一批准用于临床检测CTCs的产品(主要针对乳腺癌及前列腺癌)[17],它的应用主要基于CTCs特异的高表达的上皮分子相关抗原(如EpCAM、CK等)。但经过神经上皮间质转换过程(GMT)的胶质母细胞瘤CTCs,EpCAM、CK的表达缺失[18],使CellSearch系统无法应用于胶质母细胞瘤CTCs与外周血细胞的分离,因此识别胶质母细胞瘤CTCs需要新的免疫分子。所以高敏感、高特异的辨识因子和检测手段标准化应用,是当下胶质母细胞瘤CTCs研究重点所在。

    如何检测胶质母细胞瘤CTCs,科学家们设计多种方法。Müller等[3]曾采集141例GBM患者血液,与健康者血液对照,通过离心法富集血液中所有细胞,用胶质原纤维酸性蛋白(glial fibrillary acidic protein, GFAP)免疫染色的方法识别CTCs,结果显示GFAP阳性率为20.6%。而这些GFAP阳性的细胞呈现表皮生长因子受体(epidermal growth factor receptor, EGFR)基因的表达明显上调。Sullivan等[4]通过微流体技术——CTC-iChip富集87例GBM患者血液中的细胞,再用一组胶质瘤标志物(SOX2、tubulinbeta-3、EGFR、A2B5和c-Met)进行CTCs的识别,结果在27例GBM患者血液中发现了CTCs,还发现一些与侵袭性相关的基因(如SERPINE1、TGFB1、TGFBR2和vimentin等)在这些CTCs中高表达。

    Macarthur等[6]使用物理离心法富集血细胞,然后用含人端粒酶反转录酶启动子和绿色荧光蛋白(green fluorescent protein, GFP)表达盒的腺病毒感染所得细胞,使细胞能在端粒酶反转录酶的作用下激活(GFP telomerase-based assay),结果发现11例患者中有8例(72%)为CTCs阳性,而在8例经放疗的高级别胶质瘤患者血液中仅1例(12%)CTCs阳性。Zhang等[7]用类似的方法(所选择的病毒不同)检测了290例肿瘤患者及178例正常人血液样本,肿瘤病例包括肺癌、结肠癌、胃癌、肝癌、胰腺癌及胶质瘤,其中CTCs阳性患者为219(75.5%)例,而在39胶质瘤患者中,CTCs阳性为23(59%)例。

    CTCs是否存在于早期的GBM患者血液中目前仍有争议。理论上GBM自形成之后,便存在GMT特性,不断的尝试将自身细胞释放入血,并企图在其他环境下进行无性繁殖[19]。因此,CTCs检测理论上能更早于影像学发现GBM。而临床上占位明确的颅内肿瘤患者,很难对肿瘤进行准确的定性分级,影响GBM患者治疗方案的选择,进而影响了GBM患者的总体预后。因此早期的分类定性GBM,相当于术前肿瘤的活体检查,将会给临床的治疗决策和改善患者的预后带来巨大的收益。例如,在以往不同版本的颅内肿瘤治疗指南中,手术切除、联合放射和化学治疗是治疗GBM的总原则,未经手术的经验型化疗及放疗方案,常因错判治疗的敏感度而延误最佳治疗时期,不仅影响治疗效果,而且增加患者经济负担。而术前CTCs的检测可以在基因和细胞层面早期评估肿瘤恶性程度,使临床工作者更迅速地预知放疗和化疗个体方案对患者治疗的敏感度,更利于肿瘤的规范化、个体化治疗,提高患者疗效,延长总体生存时间,并改善生存质量。

    GBM由于极差的预后而受到广泛的关注,在手术、放化疗多种方案的结合下,预后仍不良,这是因为GBM的恶性程度高和临床上缺乏及时准确的检测手段。近年来,随着生物检测技术的发展,CTCs被证明存在于GBM患者血液中,它具有肿瘤干细胞特性,能够被多种生物标记检测到,但现有的检测技术仍未标准和规范化。

    胶质母细胞瘤CTCs的发现让我们看到了新的希望:(1)CTCs有望较影像学更早更及时地发现肿瘤;(2)CTCs有望成为术前准确诊断肿瘤的手段,指导临床治疗工作;(3)CTCs有望成为评估肿瘤复发的关键指标。当下寻找高敏感度的CTCs免疫标志物、优化检测手段是胶质母细胞瘤CTCs检测研究的重难点,目前CTCs的临床价值仍需更大量的研究数据评估。

  • 图  1   干扰LSD1表达后Foxo3a蛋白水平变化

    Figure  1   Knockdown of LSD1 upregulated Foxo3a protein levels

    图  2   Transwell实验检测四组卵巢癌细胞的迁移情况(×200)

    Figure  2   Metastasis of ovarian cancer cells in four groups detected by Transwell assay (×200)

    图  3   Foxo3a介导LSD1对EMT相关蛋白表达的调控

    Figure  3   Foxo3a mediated the regulation of LSD1 on EMT-related protein expression

    表  1   四组卵巢癌细胞的生长抑制情况(x±s)

    Table  1   Proliferation of ovarian cancer cells in four groups(x±s)

    下载: 导出CSV

    表  2   四组卵巢癌细胞的迁移情况(x±s)

    Table  2   Metastasis of ovarian cancer cells in four groups (x±s)

    下载: 导出CSV
  • [1]

    Maldonado L, Hoque MO. Epigenomics and ovarian carcinoma[J]. Biomark Med, 2010, 4(4): 543-70. doi: 10.2217/bmm.10.72

    [2]

    Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010[J]. CA Cancer J Clin, 2010, 60(5): 277-300. doi: 10.3322/caac.20073

    [3]

    Cao C, Vasilatos SN, Bhargava R, et al. Functional interaction of histone deacetylase 5 (hdac5) and lysine-specific demethylase 1 (lsd1) promotes breast cancer progression[J]. Oncogene, 2017, 36(1): 133-45. doi: 10.1038/onc.2016.186

    [4]

    Amente S, Milazzo G, Sorrentino MC, et al. Lysine-specific demethylase (lsd1/kdm1a) and mycn cooperatively repress tumor suppressor genes in neuroblastoma J]. Oncotarget, 2015, 6(16): 14572-83. http://pubmedcentralcanada.ca/pmcc/articles/PMC4546488/

    [5]

    Sakamoto A, Hino S, Nagaoka K, et al. Lysine demethylase lsd1 coordinates glycolytic and mitochondrial metabolism in hepatocellular carcinoma cells[J]. Cancer Res, 2015, 75(7): 1445-56. doi: 10.1158/0008-5472.CAN-14-1560

    [6]

    Zhang X, Zhang X, Yu B, et al. Oncogene lsd1 is epigenetically suppressed by mir-137 overexpression in human non-small cell lung cancer [J]. Biochimie, 2017, 137: 12-9. doi: 10.1016/j.biochi.2017.02.010

    [7]

    Kauffman EC, Robinson BD, Downes MJ, et al. Role of androgen receptor and associated lysine-demethylase coregulators, lsd1 and jmjd2a, in localized and advanced human bladder cancer[J]. Mol Carcinog, 2011, 50(12): 931-44. doi: 10.1002/mc.20758

    [8]

    Mould DP, McGonagle AE, Wiseman DH, et al. Reversible inhibitors of lsd1 as therapeutic agents in acute myeloid leukemia: Clinical significance and progress to date[J]. Med Res Rev, 2015, 35(3): 586-618. doi: 10.1002/med.2015.35.issue-3

    [9]

    Konovalov S, Garcia-bassets I. Analysis of the levels of lysine-specific demethylase 1 (lsd1) mrna in human ovarian tumors and the effects of chemical lsd1 inhibitors in ovarian cancer cell lines [J]. J Ovarian Res, 2013, 6(1): 75. doi: 10.1186/1757-2215-6-75

    [10] 刘秀文, 魏野, 李袁霞, 等.沉默LSD1基因的表达可抑制卵巢癌H0890细胞的增殖并诱导其凋亡[J].肿瘤, 2016, 36(5): 485-95. http://kns.cnki.net/KCMS/detail/detail.aspx?filename=zzll201605001&dbname=CJFD&dbcode=CJFQ

    Liu XW, Wei Y, Li YX, et al. LSD1 gene-silencing inhibits proliferation and promotes apoptosis of ovarian cancer H08910 cells[J]. Zhong Liu, 2016, 36(5): 485-95. http://kns.cnki.net/KCMS/detail/detail.aspx?filename=zzll201605001&dbname=CJFD&dbcode=CJFQ

    [11]

    Lin H, Dai T, Xiong H, et al. Unregulated mir-96 induces cell proliferation in human breast cancer by downregulating transcriptional factor foxo3a[J]. PLoS One, 2010, 5(12): e15797. http://www.ncbi.nlm.nih.gov/pubmed/21203424/

    [12]

    Mandinova A, Lefort K, Tommasi di Vignano A, et al. The FoxO3a gene is a key negative target of canonical notch signalling in the keratinocyte UVB response[J]. EMBO J, 2008, 27(8): 1243-54. doi: 10.1038/emboj.2008.45

    [13]

    Schulte JH, Lim S, Schramm A, et al. Lysine-specific demethy lase1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy[J]. Cancer Res, 2009, 65(5): 2065-71. http://cn.bing.com/academic/profile?id=f14e5d066d7cfffd2a36247f95dd323b&encoded=0&v=paper_preview&mkt=zh-cn

    [14]

    Huang Y, Nayak S, Jankowitz R, et al. Epigenetics in breast cancer: What's new?[J]. Breast Cancer Res, 2011, 13(6): 225. doi: 10.1186/bcr2925

    [15]

    Lv T, Yuan D, Miao X, et al. Over-expression of lsd1 promotes proliferation, migration and invasion in non-small cell lung cancer [J]. PLoS One, 2012, 7(4): e35065. doi: 10.1371/journal.pone.0035065

    [16]

    Katoh M, Igarashi M, Fukuda H, et al. Cancer genetics and genomics of human fox family genes[J]. Cancer Lett, 2013, 328(2): 198-206. doi: 10.1016/j.canlet.2012.09.017

    [17]

    Boix L, López-Oliva JM, Rhodes AC, et al. Restoring mir122 in human stem-like hepatocarcinoma cells, prompts tumor dormancy through smad-independent tgf-β pathway[J]. Oncotarget, 2016, 7(44): 71309-29. http://pubmedcentralcanada.ca/pmcc/articles/PMC5342080/?report=reader

    [18]

    Cheng CW, Chen PM, Hsien YH, et al. Foxo3a-mediated overexpression of microrna-622 suppresses tumor metastasis by repressing hypoxia-inducible factor-1α in erk-responsive lung cancer[J]. Oncotarget, 2015, 6(42): 44222-38. http://www.ncbi.nlm.nih.gov/pubmed/26528854

    [19]

    Yang XB, Zhao JJ, Huang CY, et al. Decreased expression of the foxo3a gene is associated with poor prognosis in primary gastric adenocarcinoma patients[J]. PLoS One, 2013, 8(10): e78158. doi: 10.1371/journal.pone.0078158

    [20]

    Das TP, Suman S, Alatassi H, et al. Inhibition of akt promotes foxo3a-dependent apoptosis in prostate cancer[J]. Cell Death Dis, 2016, 7: e2111. doi: 10.1038/cddis.2015.403

    [21]

    Kocak C, Kocak FE, Bayhan Z, et al. Value of immunohistochemical detection of foxo3a as a prognostic marker in human breast carcinoma[J]. Inter J Clin Expe Pathol, 2016, 9(10): 9938-50. http://www.researchgate.net/publication/309618777_Value_of_immunohistochemical_detection_of_FOXO3a_as_a_prognostic_marker_in_human_breast_carcinoma

    [22]

    Obradorhevia A, Serra-sitjar M, Rodríguez J, et al. The tumour suppressor foxo3 is a key regulator of mantle cell lymphoma proliferation and survival[J]. Br J Haematol, 2012, 156(3): 334-45. doi: 10.1111/bjh.2012.156.issue-3

    [23]

    Jiang Y, Zou L, Lu WQ, et al. Foxo3a expression is a prognostic marker in breast cancer[J]. PLoS One, 2013, 8(8): e70746. doi: 10.1371/journal.pone.0070746

    [24]

    Miller BH, Wahlestedt C. MicroRNA dysregulation in psychiatric disease[J]. Brain Res, 2010, 1338: 89-99. doi: 10.1016/j.brainres.2010.03.035

    [25]

    Feng S, Jin Y, Cui M, et al. Lysine-specific demethylase 1 (lsd1) inhibitor s2101 induces autophagy via the akt/mtor pathway in skov3 ovarian cancer cells[J]. Med Sci Monit, 2016, 22: 4742-8. doi: 10.12659/MSM.898825

    [26]

    Marlow LA, von Roemeling CA, Cooper SJ, et al. Foxo3a drives proliferation in anaplastic thyroid carcinoma through transcriptional regulation of cyclin a1: A paradigm shift that impacts current therapeutic strategies[J]. J Cell Sci, 2012, 125(18): 4253-63. doi: 10.1242/jcs.097428

图(3)  /  表(2)
计量
  • 文章访问数:  1202
  • HTML全文浏览量:  397
  • PDF下载量:  354
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-12-04
  • 修回日期:  2018-02-21
  • 网络出版日期:  2024-01-12
  • 刊出日期:  2018-08-24

目录

/

返回文章
返回
x 关闭 永久关闭